Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

It's been a while since Clarkson nabbed a movie role as full-scale and invigorating as the one she has in "Lilly," a ...

President Donald Trump's second term in office has been challenging for investors, at least so far. Trump imposed sweeping ...

Writer and director Rachel Feldman reflects on her heroine Lilly Ledbetter and all the mothers that helped bring her biopic ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

The Oscar-nominated actress talks about playing the activist whose 1990s lawsuit demanding equal pay with her male colleagues went all the way to the Supreme Court, and how her own mother inspired her ...

Eli Lilly and Company (NYSE: LLY) and Purdue University announced Friday (May 9) a significant expansion of their ...

Eli Lilly (NYSE:LLY) said Thursday that Ilya Yuffa, executive vice president and president, Lilly International, will become ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...

People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the medications.